文献速递胸部肿瘤

III期非小细胞肺癌放疗后心脏毒性:70至90 Gy剂量递增试验的汇总分析

Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
PubMed 文献 · J Clin Oncol · 2017-01-23

该汇总分析纳入1996至2009年6项前瞻性剂量递增试验中127例接受70至90 Gy放疗的III期非小细胞肺癌患者,分析112例,中位随访8.8年显示26例(23%)发生症状性心脏事件,心脏剂量与基线心脏风险独立相关,心脏平均剂量≥20 Gy者2年事件率21%。

要点

  • 心脏平均剂量每增加1 Gy,症状性心脏事件风险HR为1.03(P=0.002)。
  • 心脏平均剂量<10 Gy、10-20 Gy、≥20 Gy的2年竞争风险调整事件率分别为4%、7%、21%。
  • 心脏剂量与总生存无关,但心脏毒性可能比既往认识出现更早,应尽量降低心脏剂量。

核心结论

  • 高剂量胸部放疗后症状性心脏事件相对常见,且与心脏剂量和基线心脏风险独立相关。
  • III期非小细胞肺癌放疗后心脏毒性可能比历史认识出现更早,应尽量降低心脏剂量。

研究设计与样本

  • 汇总分析1996至2009年6项前瞻性剂量递增试验,127例III期非小细胞肺癌患者接受70至90 Gy放疗(中位74 Gy),实际分析112例。

主要发现

  • 26例(23%)发生至少一次症状性心脏事件,至首次事件中位时间26个月,其中心包积液7例、心肌梗死5例、不稳定型心绞痛3例、心包炎2例、心律失常12例、心力衰竭1例。
  • 单因素分析显示心脏剂量(如心脏平均剂量,HR 1.03/Gy,P=0.002)、冠状动脉疾病(P<0.001)和WHO/国际高血压学会评分(P=0.04)与事件相关。
  • 多因素分析纳入基线风险后,心脏剂量仍显著相关。
  • 心脏平均剂量<10 Gy、10至20 Gy、≥20 Gy患者的2年竞争风险调整事件率分别为4%、7%、21%。
  • 心脏剂量与总生存无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The significance of radiotherapy (RT) -associated cardiac injury for stage III non-small-cell lung cancer (NSCLC) is unclear, but higher heart doses were associated with worse overall survival in the Radiation Therapy Oncology Group (RTOG) 0617 study. We assessed the impact of heart dose in patients treated at our institution on several prospective dose-escalation trials. Patients and Methods From 1996 to 2009, 127 patients with stage III NSCLC (Eastern Cooperative Oncology Group performance status, 0 to 1) received dose-escalated RT to 70 to 90 Gy (median, 74 Gy) in six trials. RT plans and cardiac doses were reviewed. Records were reviewed for the primary end point: symptomatic cardiac events (symptomatic pericardial effusion, acute coronary syndrome, pericarditis, significant arrhythmia, and heart failure). Cardiac risk was assessed by noting baseline coronary artery disease and calculating the WHO/International Society of Hypertension score. Competing risks analysis was used. Results In all, 112 patients were analyzed. Median follow-up for surviving patients was 8.8 years. Twenty-six patients (23%) had one or more events at a median of 26 months to first event (effusion [n = 7], myocardial infarction [n = 5], unstable angina [n = 3], pericarditis [n = 2], arrhythmia [n = 12], and heart failure [n = 1]). Heart doses (eg, heart mean dose; hazard ratio, 1.03/Gy; P = .002,), coronary artery disease ( P < .001), and WHO/International Society of Hypertension score ( P = .04) were associated with events on univariable analysis. Heart doses remained significant on multivariable analysis that accounted for baseline risk. Two-year competing risk-adjusted event rates for patients with heart mean dose < 10 Gy, 10 to 20 Gy, or ≥ 20 Gy were 4%, 7%, and 21%, respectively. Heart doses were not associated with overall survival. Conclusion Cardiac events were relatively common after high-dose thoracic RT and were independently associated with both heart dose and baseline cardiac risk. RT-associated cardiac toxicity after treatment of stage III NSCLC may occur earlier than historically understood, and heart doses should be minimized.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wang K, Eblan MJ, Deal AM, et al. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. J Clin Oncol. 2017. PMID: 28113017. doi:10.1200/JCO.2016.70.0229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。